Park Place Capital Corp Purchases 1,335 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Park Place Capital Corp lifted its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 115.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,492 shares of the company’s stock after purchasing an additional 1,335 shares during the period. Park Place Capital Corp’s holdings in Privia Health Group were worth $49,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in PRVA. Northern Trust Corp grew its position in Privia Health Group by 28.7% during the third quarter. Northern Trust Corp now owns 1,344,327 shares of the company’s stock worth $30,920,000 after buying an additional 299,395 shares in the last quarter. Gotham Asset Management LLC grew its position in Privia Health Group by 97.9% during the third quarter. Gotham Asset Management LLC now owns 59,557 shares of the company’s stock worth $1,370,000 after buying an additional 29,465 shares in the last quarter. Glenmede Trust Co. NA grew its position in Privia Health Group by 0.9% during the third quarter. Glenmede Trust Co. NA now owns 107,711 shares of the company’s stock worth $2,477,000 after buying an additional 976 shares in the last quarter. Walleye Capital LLC acquired a new stake in Privia Health Group during the third quarter worth approximately $1,394,000. Finally, Wellington Management Group LLP grew its position in Privia Health Group by 1.0% during the third quarter. Wellington Management Group LLP now owns 4,656,685 shares of the company’s stock worth $107,104,000 after buying an additional 45,639 shares in the last quarter. Institutional investors own 94.48% of the company’s stock.

Insider Buying and Selling

In related news, Director Adam Boehler bought 277,565 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was acquired at an average cost of $16.17 per share, with a total value of $4,488,226.05. Following the transaction, the director now directly owns 5,488,701 shares in the company, valued at $88,752,295.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Adam Boehler bought 277,565 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was acquired at an average cost of $16.17 per share, with a total value of $4,488,226.05. Following the transaction, the director now directly owns 5,488,701 shares in the company, valued at $88,752,295.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas Bartrum sold 2,252 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total value of $41,481.84. Following the transaction, the executive vice president now directly owns 103,862 shares of the company’s stock, valued at $1,913,138.04. The disclosure for this sale can be found here. In the last three months, insiders purchased 293,235 shares of company stock valued at $4,745,481 and sold 45,457 shares valued at $827,810. 14.20% of the stock is owned by corporate insiders.

Privia Health Group Stock Down 1.6 %

NASDAQ PRVA opened at $17.10 on Tuesday. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $28.23. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 114.00, a price-to-earnings-growth ratio of 2.72 and a beta of 0.78. The business’s fifty day moving average is $17.48 and its 200 day moving average is $19.71.

Privia Health Group (NASDAQ:PRVA) last announced its earnings results on Thursday, May 9th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.03). The company had revenue of $415.24 million for the quarter, compared to the consensus estimate of $435.07 million. Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. On average, research analysts anticipate that Privia Health Group, Inc. will post 0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price target on Privia Health Group from $38.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 6th. Citigroup began coverage on Privia Health Group in a report on Monday, April 22nd. They issued a “buy” rating and a $25.00 target price on the stock. Robert W. Baird began coverage on Privia Health Group in a report on Thursday, May 30th. They issued an “outperform” rating and a $23.00 target price on the stock. Stifel Nicolaus reduced their target price on Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Finally, Baird R W raised Privia Health Group to a “strong-buy” rating in a report on Thursday, May 30th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.92.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.